



## FINAL PROGRAMME

### FRIDAY 2 FEBRUARY 2024

09:30-12:00 Breast Cancer Task Force - moderators: Hans Wildiers and Ahmad Awada

09:30 Who are candidates for neoadjuvant chemotherapy in luminal disease? - Françoise Derouane, UZ Leuven

09:55 Targeted axillary dissection after neoadjuvant chemotherapy in cN+ disease

- Ines Nevelsteen, UZ Leuven

10:20 Challenges in the approach of brain metastases in breast cancer - Nuria Kotecki, Institut Jules Bordet

10:45 How to select optimal adjuvant endocrine therapy in early HR+ breast cancer?

- Kevin Punie, Ziekenhuizen GasthuisZusters Antwerpen

11:10 **MEMBERS ONLY**

Open group discussion about standard practice, clinical trials and organizational aspects of breast cancer care - Ahmad Awada, Institut Jules Bordet and Hans Wildiers, UZ Leuven

12:00-12:30 General Assembly **MEMBERS ONLY**

12:30-14:00 Break

13:00-13:30 Lunchtime Satellite Symposium by Alliance AstraZeneca- Daiichi Sankyo

Interdisciplinary View on HER2-Low Breast Cancer

- Navigating new horizons: how to identify HER2-low breast cancer?

- Gabriela Beniuga, IPG, Institut de Pathologie et de Génétique

- Breaking the swimlanes with HER2-low breast cancer

- François Duhoux, Institut Roi Albert II, Cliniques Universitaires Saint-Luc

14:00-15:30 Update in gynaecological cancers - moderators: Christine Gennigens and Eline Naert

14:00 Cervical cancer - Christine Gennigens, CHU Liège

14:25 Endometrial cancer - Hannelore Denys, UZ Gent

14:50 Ovarian cancer - Jean-François Baurain, UCLouvain

15:15 Interactive discussion between panel and public

15:30-16:00 Break

16:00-17:30 Proffered papers by junior members - moderators: Cédric Van Marcke and Marthe Verhaert

16:00 The impact of drug-drug interactions between palbociclib and proton pump inhibitors on clinical outcomes of patients with hormone receptor positive, HER2-negative, early breast cancer: an exploratory analysis of the PALLAS study - Elisa Agostinetto, Institut Jules Bordet

16:10 Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program - Kristien Borremans, UZ Leuven

16:20 The role of whole genome doubling in immune escape in TNBC - Pierre Foidart, CHU Liège

16:30 Multi-omics and spatial architecture of antigenic macrophage-CD8+ T cell crosstalk predicts clinical benefit of immunotherapy in renal cell carcinoma - Lisa Kinget, KU & UZ Leuven

16:40 A double-edged role of NK cells in anti-PD1 based immune checkpoint inhibition in melanoma - Ewout Landeloos, UZ Leuven

16:50 Molecular characterization of the histopathological growth patterns of colorectal cancer liver metastases by RNA sequencing of targeted samples at the tumor-liver interface - Emily Latacz, GZA Hospitals

17:00 Real-world experience with sorafenib for advanced and refractory desmoid-type fibromatosis - Delphine Schampers, UZ Gent

17:10 Beyond Information: Revealing Alarming Decision-Making Results in Coping with Immune-Related Adverse Events through Hypothetical Scenarios - An illustration through the Immuno'Act© acceptance study - Sylvie Streel, CHU Liège

17:30-17:45 Pfizer Award Presentation 2021 - introduced by Kevin Punie

Preventing emotion dysregulation in metastatic breast cancer patients: A randomized study assessing the efficacy of a personalized multimodal intervention versus a guided self-help intervention - Florence Lewis and Sadio Righes, Institut Jules Bordet & ULB

17:45-18:00 Summary and closing day 1 - Evandro de Azambuja

Abstract authors awarded with a poster presentation must present their scientific poster in the poster area from Friday morning until Saturday afternoon



## SATURDAY 3 FEBRUARY 2024

08:30-09:30 Supportive Care Task Force - moderators: Christel Fontaine and Jean Klastersky

08:30 "Integrative Medicine: How It Helps Cancer Supportive Care"- Gary Deng, Memorial Sloan Kettering Cancer Center

09:00 Health education according to the charter of Ottawa - Antonietta Iasiello, Clinica Dr Spinedi

09:30-10:00 Disparities in oncological care - Peter Vuylsteke, University of Botswana  
introduced by Florence Van Ryckeghem

10:00-10:30 What you should not have missed in 2023 - Ahmad Awada, Institut Jules Bordet  
introduced by Barbara Brouwers

10:30-11:00 Break

11:00-11:15 Breast Cancer Research Awards 2024

introduced by Sonja Buyle, Sr Medical Director Gilead Sciences Belgium-Luxembourg

11:15-12:30 Academic session - moderators: Willem Lybaert and Annelies Verbiest

11:15 Updated results of the BALLETT trial - Brigitte Maes, Jessa Ziekenhuis

11:30 Major breakthroughs in digestive oncology - Jeroen Dekervel, UZ Leuven

12:00 AI-augmented oncologic imaging: the roadmap to clinical excellence and practice growth  
- Sergey Morozov, Osimis

12:30-12:45 Best junior abstracts ceremony - Cédric Van Marcke and Marthe Verhaert

12:45-13:00 Closing remarks - Evandro de Azambuja

13:00-14:00 Break

14:00-14:05 Introduction - Anouk Goudsmit, Institut Jules Bordet

14:05-15:35 BSMO Young Oncologists Committee (YOC) session - Part 1 **Toxicity**  
moderators: Delphine Schampers and Alexander Decruyenaere

14:05 AE of the Antibody Drug Conjugates - Kevin Punie, Ziekenhuizen GasthuisZusters Antwerpen

14:35 Neurotoxicity of immune checkpoint inhibitors - Laura Seynaeve, UZ Brussel

15:05 Skin toxicities: tips and tricks - Jolien Kessels, UZ Brussel

15:35-16:05 Break

16:05-17:35 BSMO Young Oncologists Committee (YOC) session - Part 2 **Personalized Medicine**  
moderators: Jeremy Blanc and Tim Wessels

16:05 Interpretation of a NGS report - Brigitte Maes, Jessa Ziekenhuis

16:35 Clinical application of a liquid biopsy - Michail Ignatiadis, Institut Jules Bordet

17:05 Cellular vaccines and CAR-T in 2023 - Fabio Andreozzi, Institut Jules Bordet

17:35-17:40 Closing remarks - Marthe Verhaert, UZ Brussel

17:40-18:40 BSMO YOC reception

NEW